Literature DB >> 8461922

Cognitive impairment and autoantibodies in systemic lupus erythematosus.

J G Hanly1, N M Walsh, J D Fisk, B Eastwood, C Hong, G Sherwood, J V Jones, E Jones, K Elkon.   

Abstract

Nervous system involvement in systemic lupus erythematosus (SLE) includes a wide array of manifestations some of which have been associated with specific autoantibodies. These include reactivity to surface neuronal and lymphocyte antigens, ribosomal P and cardiolipin. The aim of the present study was to examine the association between cognitive abnormalities and these autoantibodies in an unselected female population of SLE patients. Using a battery of standardized neuropsychological tests, cognitive impairment was identified in 15/70 (21%) SLE patients compared to 1/25 (4%) patients with rheumatoid arthritis and 1/23 (4%) healthy subjects (P = 0.04). Circulating antineuronal antibodies were measured by indirect immunofluorescence using human neuroblastoma cell lines IMR-6 and SK-N-SH. Lymphocytotoxic antibodies were measured by microcytotoxicity. Antibodies to ribosomal P and cardiolipin were measured by ELISA. Antineuronal antibodies were detected in 34%, lymphocytotoxic antibodies in 47%, anti-P antibodies in 17% and anticardiolipin antibodies in 24% of patients. In the cognitively impaired and unimpaired SLE patients there was no significant difference in the prevalence of antineuronal antibodies (33 vs 35%), lymphocytotoxic antibodies (40 vs 50%), anti-P antibodies (20 vs 17%) or anticardiolipin antibodies (7 vs 29%). The titre and isotype of autoantibodies were also similar in both groups. These results suggest that autoantibodies which have previously been associated with nervous system manifestations of SLE are not likely to be directly involved in the pathogenesis of cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461922     DOI: 10.1093/rheumatology/32.4.291

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  16 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

2.  Central nervous system (CNS) involvement in SLE. The diagnostic role of antibodies to neuronal antigens.

Authors:  I J Alosachie; J W Terryberry; D Mevorach; Y Chapman; M Lorber; D Torre; P Youinou; J B Peter; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.

Authors:  Melanie J Harrison; Lisa D Ravdin
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes.

Authors:  Elizabeth Kozora; Sterling G West; Steven F Maier; Christopher M Filley; David B Arciniegas; Mark Brown; David Miller; Alex Grimm; Lening Zhang
Journal:  J Neurol Sci       Date:  2010-05-23       Impact factor: 3.181

Review 5.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

6.  Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial.

Authors:  Michelle Petri; Mohammad Naqibuddin; Margaret Sampedro; Roald Omdal; Kathryn A Carson
Journal:  Semin Arthritis Rheum       Date:  2011-04-01       Impact factor: 5.532

Review 7.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

Review 8.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

9.  A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus.

Authors:  E M Hay; A Huddy; D Black; P Mbaya; B Tomenson; R M Bernstein; P J Lennox Holt; F Creed
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

10.  Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Authors:  Michael E Luggen; Gaurav Gulati; Bin Zhang; Rohan A Willis; Emilio B Gonzalez
Journal:  Clin Rheumatol       Date:  2015-11-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.